Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has represented Acast in connection with EUR 25 million financing from EIB
Mandate

Vinge has represented Acast in connection with EUR 25 million financing from EIB

August 30, 2019 Banking and Finance

The Swedish leading podcast company Acast has signed a EUR 25 million financing agreement with the European Investment Bank (EIB).  

The EIB financing is supported by the European Fund for Strategic Investments (EFSI), the main pillar of the Investment Plan for Europe (known as the ”Juncker Plan”), the purpose of which is to provide alternative sources of financing to innovative companies. The financing agreement provides a ”quasi-equity” financing without resulting in EIB owning any shares in Acast. 

Acast was founded in 2014, has its headquarters in Stockholm and services available in ten different countries. 

Vinge’s team included Sofia Törnroth Nyberg and Albert Wållgren (Banking & Finance), and Johan Larsson and Vilhelm Rondahl (M&A).
 

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026